Iambic Therapeutics, Inc. (NASDAQ:IAM) Stock Has Average Target Price of $27.25 According to Analysts

Shares of Iambic Therapeutics, Inc. (NASDAQ:IAM) have earned a consensus rating of “Moderate Buy” from the five analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $27.25.

A number of research analysts recently weighed in on IAM shares. JPMorgan Chase & Co. began coverage on shares of Iambic Therapeutics in a research note on Monday. They set an “overweight” rating and a $22.00 target price on the stock. Jefferies Financial Group assumed coverage on Iambic Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $35.00 price objective on the stock. Wall Street Zen raised Iambic Therapeutics to a “hold” rating in a research note on Saturday, November 7th. Citigroup started coverage on Iambic Therapeutics in a research report on Monday. They set a “buy” rating and a $22.00 target price for the company. Finally, Bank of America began coverage on Iambic Therapeutics in a report on Monday. They issued a “buy” rating and a $30.00 price target on the stock.

Insider Transactions at Iambic Therapeutics

In related news, Director Evan Lockwood Rachlin acquired 718,750 shares of Iambic Therapeutics stock in a transaction dated Friday, October 16th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $11,500,000.00. Following the completion of the transaction, the director directly owned 2,588,248 shares in the company, valued at approximately $41,411,968. This represents a 38.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 22.90% of the stock is currently owned by company insiders.

Iambic Therapeutics Stock Up 4.1%

IAM stock opened at $15.39 on Thursday. Iambic Therapeutics has a twelve month low of $9.60 and a twelve month high of $25.00.

Iambic Therapeutics Company Profile

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.